Heritage Investors Management Corp buys $19,290,097 stake in Amgen (AMGN)

Amgen (AMGN) : Heritage Investors Management Corp scooped up 484 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 15, 2016. The investment management firm now holds a total of 118,395 shares of Amgen which is valued at $19,290,097.Amgen makes up approximately 1.40% of Heritage Investors Management Corp’s portfolio.

Other Hedge Funds, Including , Sumitomo Life Insurance Co reduced its stake in AMGN by selling 1,112 shares or 3.4% in the most recent quarter. The Hedge Fund company now holds 31,604 shares of AMGN which is valued at $5,149,240. Amgen makes up approx 0.68% of Sumitomo Life Insurance Co’s portfolio.Sarasin Partners Llp reduced its stake in AMGN by selling 178,880 shares or 11.92% in the most recent quarter. The Hedge Fund company now holds 1,321,724 shares of AMGN which is valued at $215,348,491. Amgen makes up approx 3.45% of Sarasin Partners Llp’s portfolio.Atria Investments reduced its stake in AMGN by selling 175 shares or 2.54% in the most recent quarter. The Hedge Fund company now holds 6,707 shares of AMGN which is valued at $1,076,608. Amgen makes up approx 0.11% of Atria Investments’s portfolio.Creative Planning boosted its stake in AMGN in the latest quarter, The investment management firm added 3,503 additional shares and now holds a total of 67,175 shares of Amgen which is valued at $10,782,931. Amgen makes up approx 0.08% of Creative Planning’s portfolio.

Amgen closed down -0.35 points or -0.21% at $162.93 with 18,15,610 shares getting traded on Monday. Post opening the session at $163.82, the shares hit an intraday low of $162.79 and an intraday high of $164 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *